Fisher information matrix for nonlinear mixed effects multiple response models: Evaluation of the appropriateness of the first order linearization using a pharmacokinetic/pharmacodynamic model

We focus on the Fisher information matrix used for design evaluation and optimization in nonlinear mixed effects multiple response models. We evaluate the appropriateness of its expression computed by linearization as proposed for a single response model. Using a pharmacokinetic-pharmacodynamic (PKPD) example, we first compare the computation of the Fisher information matrix with approximation to one derived from the observed matrix on a large simulation using the stochastic approximation expectation-maximization algorithm (SAEM). The expression of the Fisher information matrix for multiple responses is also evaluated by comparison with the empirical information obtained through a replicated simulation study using the first-order linearization estimation methods implemented in the NONMEM software (first-order (FO), first-order conditional estimate (FOCE)) and the SAEM algorithm in the MONOLIX software. The predicted errors given by the approximated information matrix are close to those given by the information matrix obtained without linearization using SAEM and to the empirical ones obtained with FOCE and SAEM. The simulation study also illustrates the accuracy of both FOCE and SAEM estimation algorithms when jointly modelling multiple responses and the major limitations of the FO method. This study highlights the appropriateness of the approximated Fisher information matrix for multiple responses, which is implemented in PFIM 3.0, an extension of the R function PFIM dedicated to design evaluation and optimization. It also emphasizes the use of this computing tool for designing population multiple response studies, as for instance in PKPD studies or in PK studies including the modelling of the PK of a drug and its active metabolite.

[1]  É. Moulines,et al.  Convergence of a stochastic approximation version of the EM algorithm , 1999 .

[2]  Malcolm Rowland,et al.  Optimal Design for Multivariate Response Pharmacokinetic Models , 2006, Journal of Pharmacokinetics and Pharmacodynamics.

[3]  Mats O. Karlsson,et al.  Comparison of some practical sampling strategies for population pharmacokinetic studies , 1996, Journal of Pharmacokinetics and Biopharmaceutics.

[4]  Eric Walter,et al.  Identification of Parametric Models: from Experimental Data , 1997 .

[5]  France Mentré,et al.  Optimization of Individual and Population Designs Using Splus , 2003, Journal of Pharmacokinetics and Pharmacodynamics.

[6]  Jon Wakefield,et al.  Population modelling in drug development , 1999, Statistical methods in medical research.

[7]  Paolo Vicini,et al.  Simultaneous population optimal design for pharmacokinetic-pharmacodynamic experiments , 2005, The AAPS Journal.

[8]  Anthony C. Atkinson,et al.  Optimum Experimental Designs , 1992 .

[9]  France Mentré,et al.  Fisher information matrix for non‐linear mixed‐effects models: evaluation and application for optimal design of enoxaparin population pharmacokinetics , 2002, Statistics in medicine.

[10]  France Mentré,et al.  Development and implementation of the population Fisher information matrix for the evaluation of population pharmacokinetic designs , 2001, Comput. Methods Programs Biomed..

[11]  Lewis B. Sheiner,et al.  Simultaneous vs. Sequential Analysis for Population PK/PD Data I: Best-Case Performance , 2003, Journal of Pharmacokinetics and Pharmacodynamics.

[12]  Michel Tod,et al.  Impact of Pharmacokinetic–Pharmacodynamic Model Linearization on the Accuracy of Population Information Matrix and Optimal Design , 2001, Journal of Pharmacokinetics and Pharmacodynamics.

[13]  D. Bates,et al.  Approximations to the Log-Likelihood Function in the Nonlinear Mixed-Effects Model , 1995 .

[14]  D. Bates,et al.  Mixed-Effects Models in S and S-PLUS , 2001 .

[15]  Brian Whiting,et al.  Experimental design and efficient parameter estimation in population pharmacokinetics , 1990, Journal of Pharmacokinetics and Biopharmaceutics.

[16]  France Mentré,et al.  Extension of the SAEM algorithm to left-censored data in nonlinear mixed-effects model: Application to HIV dynamics model , 2006, Comput. Stat. Data Anal..

[17]  Alain Mallet,et al.  Optimal design in random-effects regression models , 1997 .

[18]  Marc Lavielle,et al.  Maximum likelihood estimation in nonlinear mixed effects models , 2005, Comput. Stat. Data Anal..

[19]  D. Bates,et al.  Nonlinear mixed effects models for repeated measures data. , 1990, Biometrics.

[20]  France Mentré,et al.  The SAEM algorithm for group comparison tests in longitudinal data analysis based on non‐linear mixed‐effects model , 2007, Statistics in medicine.

[21]  Goonaseelan Pillai,et al.  Non-Linear Mixed Effects Modeling – From Methodology and Software Development to Driving Implementation in Drug Development Science , 2005, Journal of Pharmacokinetics and Pharmacodynamics.

[22]  France Mentré,et al.  Further Developments of the Fisher Information Matrix in Nonlinear Mixed Effects Models with Evaluation in Population Pharmacokinetics , 2003, Journal of biopharmaceutical statistics.

[23]  Lewis B. Sheiner,et al.  Simultaneous vs. Sequential Analysis for Population PK/PD Data II: Robustness of Methods , 2003, Journal of Pharmacokinetics and Pharmacodynamics.

[24]  Gordon Graham,et al.  Optimal Design for Multiresponse Pharmacokinetic–Pharmacodynamic Models – Dealing with Unbalanced Designs , 2007, Journal of Pharmacokinetics and Pharmacodynamics.

[25]  T. Louis Finding the Observed Information Matrix When Using the EM Algorithm , 1982 .

[26]  Sergei Leonov,et al.  OPTIMAL POPULATION DESIGNS FOR PK MODELS WITH SERIAL SAMPLING , 2004, Journal of biopharmaceutical statistics.

[27]  France Mentré,et al.  Design in nonlinear mixed effects models: Optimization using the Fedorov–Wynn algorithm and power of the Wald test for binary covariates , 2007, Statistics in medicine.

[28]  Michel Tod,et al.  Evaluation of Uncertainty Parameters Estimated by Different Population PK Software and Methods , 2007, Journal of Pharmacokinetics and Pharmacodynamics.

[29]  Kathryn Chaloner,et al.  Bayesian Experimental Design for Nonlinear Mixed‐Effects Models with Application to HIV Dynamics , 2004, Biometrics.

[30]  Leon Aarons,et al.  Incorporating Correlation in Interindividual Variability for the Optimal Design of Multiresponse Pharmacokinetic Experiments , 2008, Journal of biopharmaceutical statistics.